Compare RVLV & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | ANAB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2018 | 2015 |
| Metric | RVLV | ANAB |
|---|---|---|
| Price | $23.29 | $59.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $29.73 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 906.2K | 526.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 91.02 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,225,682,000.00 | $234,603,000.00 |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | $52.14 |
| P/E Ratio | $50.30 | ★ N/A |
| Revenue Growth | 8.48 | ★ 157.01 |
| 52 Week Low | $17.35 | $17.11 |
| 52 Week High | $31.68 | $73.30 |
| Indicator | RVLV | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 54.51 |
| Support Level | $21.13 | $53.46 |
| Resistance Level | $26.97 | $68.22 |
| Average True Range (ATR) | 0.97 | 2.44 |
| MACD | -0.35 | 0.72 |
| Stochastic Oscillator | 7.92 | 85.92 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).